159 related articles for article (PubMed ID: 19174419)
1. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
Sherlock M; Toogood AA; Steeds R
Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419
[No Abstract] [Full Text] [Related]
2. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
4. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists and hyperprolactinaemia.
Martin NM; Tan T; Meeran K
BMJ; 2009 Mar; 338():b381. PubMed ID: 19258356
[No Abstract] [Full Text] [Related]
6. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
7. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
Lökk J
Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
[No Abstract] [Full Text] [Related]
8. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
9. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
[No Abstract] [Full Text] [Related]
10. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
[No Abstract] [Full Text] [Related]
11. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary complications of ergot-derivative dopamine agonists.
Rack MJ; Baran AS; Richert AC; Roffwarg HP
J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
[No Abstract] [Full Text] [Related]
13. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
[TBL] [Abstract][Full Text] [Related]
14. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
15. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Bares M; Rektorová I; Krajcovicová L; Rektor I
J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
[No Abstract] [Full Text] [Related]
16. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
17. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Senol MG; Togrol RE
Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
[No Abstract] [Full Text] [Related]
18. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
20. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
